S. Galimberti

Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?

R. Cacciola, G. Fulvio, A. di Paolo, 2023, Frontiers in medicine.

The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib

G. Caocci, C. Fozza, M. Breccia, 2023, Annals of hematology.

Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients

E. Benedetti, P. Lippolis, F. Cerri, 2023, Frontiers in oncology.

Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents

G. Buda, Maria Livia Del Giudice, S. Galimberti, 2023, Cancer Immunology, Immunotherapy.

Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy

R. Lemoli, A. Billio, R. Palmieri, 2024, Frontiers in oncology.

Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort

A. Frustaci, A. Tedeschi, A. Chiarenza, 2024, Hematological oncology.

Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany.

U. Occhini, C. Baratè, A. Gozzetti, 2023, Clinical and experimental medicine.